Merck & Co., Inc. (MRK) Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release